RAMPs as drug targets

Patrick M. Sexton, David R. Poyner, John Simms, Arthur Christopoulos, Debbie L. Hay

Research output: Contribution to journalArticle

Abstract

The receptor activity-modifying protein (RAMP) family of membrane proteins regulates G protein-coupled receptor (GPCR) function in several ways. RAMPs can alter their pharmacology and signalling as well as the trafficking of these receptors to and from the cell surface. Accordingly, RAMPs may be exploited as drug targets, offering new opportunities for regulating the function of therapeutically relevant RAMP-interacting GPCRs. For example, several small molecule antagonists of RAMP1/ calcitonin receptor-like receptor complexes, which block the actions of the neuropeptide calcitonin gene-related peptide are in development for the treatment of migraine headache.
LanguageEnglish
Pages61-74
Number of pages14
JournalAdvances in Experimental Medicine and Biology
Volume744
DOIs
Publication statusPublished - 2012

Fingerprint

Receptor Activity-Modifying Proteins
Calcitonin Receptor-Like Protein
Calcitonin Gene-Related Peptide
Cell Surface Receptors
G-Protein-Coupled Receptors
Neuropeptides
Migraine Disorders
Pharmaceutical Preparations
Membrane Proteins
Pharmacology
Molecules

Keywords

  • receptor activity-modifying proteins
  • G-protein-coupled receptors
  • signal transduction

Cite this

Sexton, Patrick M. ; Poyner, David R. ; Simms, John ; Christopoulos, Arthur ; Hay, Debbie L. / RAMPs as drug targets. In: Advances in Experimental Medicine and Biology. 2012 ; Vol. 744. pp. 61-74.
@article{c89560eb08714872af835b6134200b03,
title = "RAMPs as drug targets",
abstract = "The receptor activity-modifying protein (RAMP) family of membrane proteins regulates G protein-coupled receptor (GPCR) function in several ways. RAMPs can alter their pharmacology and signalling as well as the trafficking of these receptors to and from the cell surface. Accordingly, RAMPs may be exploited as drug targets, offering new opportunities for regulating the function of therapeutically relevant RAMP-interacting GPCRs. For example, several small molecule antagonists of RAMP1/ calcitonin receptor-like receptor complexes, which block the actions of the neuropeptide calcitonin gene-related peptide are in development for the treatment of migraine headache.",
keywords = "receptor activity-modifying proteins, G-protein-coupled receptors, signal transduction",
author = "Sexton, {Patrick M.} and Poyner, {David R.} and John Simms and Arthur Christopoulos and Hay, {Debbie L.}",
year = "2012",
doi = "10.1007/978-1-4614-2364-5_6",
language = "English",
volume = "744",
pages = "61--74",
journal = "Advances in Experimental Medicine and Biology",
issn = "0065-2598",
publisher = "Springer",

}

RAMPs as drug targets. / Sexton, Patrick M.; Poyner, David R.; Simms, John; Christopoulos, Arthur; Hay, Debbie L.

In: Advances in Experimental Medicine and Biology, Vol. 744, 2012, p. 61-74.

Research output: Contribution to journalArticle

TY - JOUR

T1 - RAMPs as drug targets

AU - Sexton, Patrick M.

AU - Poyner, David R.

AU - Simms, John

AU - Christopoulos, Arthur

AU - Hay, Debbie L.

PY - 2012

Y1 - 2012

N2 - The receptor activity-modifying protein (RAMP) family of membrane proteins regulates G protein-coupled receptor (GPCR) function in several ways. RAMPs can alter their pharmacology and signalling as well as the trafficking of these receptors to and from the cell surface. Accordingly, RAMPs may be exploited as drug targets, offering new opportunities for regulating the function of therapeutically relevant RAMP-interacting GPCRs. For example, several small molecule antagonists of RAMP1/ calcitonin receptor-like receptor complexes, which block the actions of the neuropeptide calcitonin gene-related peptide are in development for the treatment of migraine headache.

AB - The receptor activity-modifying protein (RAMP) family of membrane proteins regulates G protein-coupled receptor (GPCR) function in several ways. RAMPs can alter their pharmacology and signalling as well as the trafficking of these receptors to and from the cell surface. Accordingly, RAMPs may be exploited as drug targets, offering new opportunities for regulating the function of therapeutically relevant RAMP-interacting GPCRs. For example, several small molecule antagonists of RAMP1/ calcitonin receptor-like receptor complexes, which block the actions of the neuropeptide calcitonin gene-related peptide are in development for the treatment of migraine headache.

KW - receptor activity-modifying proteins

KW - G-protein-coupled receptors

KW - signal transduction

UR - http://www.scopus.com/inward/record.url?scp=84859791351&partnerID=8YFLogxK

UR - http://www.springerlink.com/content/m707r27l05l40w10/

U2 - 10.1007/978-1-4614-2364-5_6

DO - 10.1007/978-1-4614-2364-5_6

M3 - Article

VL - 744

SP - 61

EP - 74

JO - Advances in Experimental Medicine and Biology

T2 - Advances in Experimental Medicine and Biology

JF - Advances in Experimental Medicine and Biology

SN - 0065-2598

ER -